Y0001101
Interferon β-1a
European Pharmacopoeia (EP) Reference Standard
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
grade
pharmaceutical primary standard
API family
interferon
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
shipped in
dry ice
storage temp.
−70°C
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Interferon β-1a EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
related product
Product No.
Description
Pricing
Storage Class Code
10 - Combustible liquids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact Customer Support.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Secondary progressive multiple sclerosis: a shared therapeutic decision.
Teresa Anna Cantisani et al.
Journal of neurology, neurosurgery, and psychiatry, 84(4), 365-365 (2012-12-12)
Mohammad Amir Shahkarami et al.
Journal of immunological methods, 388(1-2), 46-48 (2012-12-12)
The appearance of neutralizing antibodies (NAbs) has significant clinical and regulatory consequences for interferons in patients with multiple sclerosis (MS). In a double blind, randomized clinical trial, 84 patients with relapsing remitting MS were enrolled in a 24month study period.
Alessandra Lugaresi
Expert opinion on drug delivery, 10(2), 273-283 (2012-12-21)
First-line disease-modifying drugs for the treatment of multiple sclerosis (MS) are mostly administered by injection. Although these treatments can control the symptoms and progression of the disease to some extent, patients often fail to adhere to their therapy in the
Robert A Bermel et al.
Annals of neurology, 73(1), 95-103 (2013-02-05)
To identify early predictors of long-term outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) treated with intramuscular (IM) interferon beta-1a (IFNβ-1a). A multicenter, observational, 15-year follow-up study of patients who completed ≥2 years in the pivotal trial of IM IFNβ-1a
M V Davydovskaia et al.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 112(9 Pt 2), 129-135 (2012-12-14)
To evaluate clinical perspectives of proton multi-voxel magnetic-resonance spectroscopy (PMMRS) for monitoring the severity of multiple sclerosis (MS) and neurodegenerative process, we studied the changes of the NAA/Cr ratio in the brain tissue of patients with MS and calculated the
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service